DÄ internationalArchive25/2008Adjuvant Chemotherapy After Complete Resection of Non-Small Cell Lung Cancer: In Reply

Correspondence

Adjuvant Chemotherapy After Complete Resection of Non-Small Cell Lung Cancer: In Reply

Dtsch Arztebl Int 2008; 105(25): 457. DOI: 10.3238/arztebl.2008.0457b

Laack, E

LNSLNS The finding of carcinomatous hemangiosis of the tumor (V1) in a completely resected non-small cell lung cancer is often associated with a higher risk of developing distant metastases at a later stage and therefore with a poorer prognosis. A large Japanese study made the same observation for tumor stage pIA (1).

To deduce from this a general recommendation for adjuvant chemotherapy in stage pIA (V1) requires prospective randomized studies of patient groups of European or North American origin. Until such studies become available, no patient with tumor stage pIA should be offered adjuvant chemotherapy outside study settings. At this point in time, sufficient evidence is lacking for adjuvant chemotherapy at stage pIA, because prospective randomized studies of unselected patient groups with regard to V1 status have so far not shown a survival advantage for adjuvant chemotherapy in patients with tumor stage pIA. DOI: 10.3238/arztebl.2008.0457b


Prof. Dr. med. Eckart Laack
II. Medizinische Klinik,
Onkologisches Zentrum
Universitätsklinikum Hamburg-Eppendorf
Martinistr. 52
20246 Hamburg, Germany
laack@uke.uni-hamburg.de

Conflict of interest statement
The authors of the letter and the reply declare that they have no conflict of interest as defined by the International Committee of Medical Journal Editors.
 1.
Tsuchiya T, Akamine S, Muraoka M et al.: Stage IA non-small cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. Lung Cancer 2007; 56: 341–8.
 1. Tsuchiya T, Akamine S, Muraoka M et al.: Stage IA non-small cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. Lung Cancer 2007; 56: 341–8.